Breath analysis in respiratory diseases: state-of-the-art and future perspectives

References

• Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc. 2014;11:404–406.
   PubMedGoogle Scholar
• Schulz S, Dickschat JS. Bacterial volatiles: the smell of small organisms. Nat Prod Rep. 2007;24:814–842.
   PubMed Web of Science ®Google Scholar
• Lemfack MC, Ravella SR, Lorenz N, et al. Novel volatiles of skin-borne bacteria inhibit the growth of gram-positive bacteria and affect quorum-sensing controlled phenotypes of gram-negative bacteria. Syst Appl Microbiol. 2016;39:503–515.
   PubMed Web of Science ®Google Scholar
• Mazzone PJ. Exhaled breath volatile organic compound biomarkers in lung cancer. J Breath Res. 2012;6:027106.
   PubMed Web of Science ®Google Scholar
• Högman M, Lehtimäki L, Dinh-Xuan AT. Utilising exhaled nitric oxide information to enhance diagnosis and therapy of respiratory disease - current evidence for clinical practice and proposals to improve the methodology. Expert Rev Respir Med. 2017;11:101–109.
   PubMed Web of Science ®Google Scholar
• Konstantinidi EM, Lappas AS, Tzortzi AS, et al. Exhaled breath condensate: technical and diagnostic aspects. Sci World J. 2015;2015:435160.
   Google Scholar
• Scarlata S, Pennazza G, Santonico M, et al. Exhaled breath analysis by electronic nose in respiratory diseases. Expert Rev Mol Diagn. 2015;15:933–956.
   PubMed Web of Science ®Google Scholar
• Gardner JW, Bartlett PN. A brief history of electronic noses. Sens Actuators B Chem. 1994;18:210–211.
   Web of Science ®Google Scholar
• Horváth I, Barnes PJ, Loukides S, et al. A European Respiratory Society technical standard: exhaled biomarkers in lung disease. Eur Respir J. 2017; 49.
   Web of Science ®Google Scholar
• GOLD. 2017. Global strategy for the diagnosis, management and prevention of COPD. [Internet]. [cited 2017 May 22]. Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/
   Google Scholar
• Bellia V, Catalano F, Pistelli R, et al. Aging on quality of spirometry. Am J Respir Crit Care Med. 2004;170:100. author reply 100–101.
   PubMedGoogle Scholar
• de Vries R, Brinkman P, van der Schee MP, et al. Integration of electronic nose technology with spirometry: validation of a new approach for exhaled breath analysis. J Breath Res. 2015;9:046001.
   PubMed Web of Science ®Google Scholar
• Fens N, Zwinderman AH, van der Schee MP, et al. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med. 2009;180:1076–1082.
   PubMed Web of Science ®Google Scholar
• Fens N, Roldaan AC, van der Schee MP, et al. External validation of exhaled breath profiling using an electronic nose in the discrimination of asthma with fixed airways obstruction and chronic obstructive pulmonary disease. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2011;41:1371–1378.
   PubMed Web of Science ®Google Scholar
• Shafiek H, Fiorentino F, Merino JL, et al. Using the electronic nose to identify airway infection during COPD exacerbations. PloS One. 2015;10:e0135199.
   PubMed Web of Science ®Google Scholar
• Finamore P, Pedone C, Lelli D, et al. Analysis of volatile organic compounds: an innovative approach to heart failure characterization in older patients. J Breath Res. 2018;12:026007.
   PubMed Web of Science ®Google Scholar
• Bofan M, Mores N, Baron M, et al. Within-day and between-day repeatability of measurements with an electronic nose in patients with COPD. J Breath Res. 2013;7:017103.
   PubMed Web of Science ®Google Scholar
• Incalzi RA, Pennazza G, Scarlata S, et al. Reproducibility and respiratory function correlates of exhaled breath fingerprint in chronic obstructive pulmonary disease. PloS One. 2012;7:e45396.
   PubMed Web of Science ®Google Scholar
• van Geffen WH, Bruins M, Kerstjens HAM. Diagnosing viral and bacterial respiratory infections in acute COPD exacerbations by an electronic nose: a pilot study. J Breath Res. 2016;10:036001.
   PubMed Web of Science ®Google Scholar
• Sibila O, Garcia-Bellmunt L, Giner J, et al. Identification of airway bacterial colonization by an electronic nose in chronic obstructive pulmonary disease. Respir Med. 2014;108:1608–1614.
   PubMed Web of Science ®Google Scholar
• Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47:410–419.
   PubMed Web of Science ®Google Scholar
• Fens N, de Nijs SB, Peters S, et al. Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD. Eur Respir J. 2011;38:1301–1309.
   PubMed Web of Science ®Google Scholar
• de Vries R, Dagelet YWF, Spoor P, et al. Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label. Eur Respir J. 2018; 51.
   Web of Science ®Google Scholar
• Couillard S, Larivée P, Courteau J, et al. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017;151:366–373.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:335–349.
   PubMed Web of Science ®Google Scholar
• Finamore P, Pedone C, Scarlata S, et al. Validation of exhaled volatile organic compounds analysis using e-nose as index of COPD severity. Int J Chron Obstruct Pulmon Dis. 2018;13:1441–1448.
   PubMed Web of Science ®Google Scholar
• Vanfleteren LEGW, Ullman A, Fabbri LM. Time for a longer and better life for patients with COPD. Eur Respir J. 2018;51:1-5.
   Web of Science ®Google Scholar
• Fens N, van Rossum AGJ, Zanen P, et al. Subphenotypes of mild-to-moderate COPD by factor and cluster analysis of pulmonary function, CT imaging and breathomics in a population-based survey. COPD. 2013;10:277–285.
   PubMedGoogle Scholar
• Scarlata S, Finamore P, Santangelo S, et al. Cluster analysis on breath print of newly diagnosed COPD patients: effects of therapy. J Breath Res. 2018;12:036022.
   PubMed Web of Science ®Google Scholar
• Hattesohl ADM, Jörres RA, Dressel H, et al. Discrimination between COPD patients with and without alpha 1-antitrypsin deficiency using an electronic nose. Respirol Carlton Vic. 2011;16:1258–1264.
   PubMed Web of Science ®Google Scholar
• Besa V, Teschler H, Kurth I, et al. Exhaled volatile organic compounds discriminate patients with chronic obstructive pulmonary disease from healthy subjects. Int J Chron Obstruct Pulmon Dis. 2015;10:399–406.
   PubMed Web of Science ®Google Scholar
• Basanta M, Ibrahim B, Dockry R, et al. Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study. Respir Res. 2012;13:72.
   PubMed Web of Science ®Google Scholar
• Van Berkel JJBN, Dallinga JW, Möller GM, et al. A profile of volatile organic compounds in breath discriminates COPD patients from controls. Respir Med. 2010;104:557–563.
   PubMed Web of Science ®Google Scholar
• Phillips CO, Syed Y, Parthaláin NM, et al. Machine learning methods on exhaled volatile organic compounds for distinguishing COPD patients from healthy controls. J Breath Res. 2012;6:036003.
   PubMed Web of Science ®Google Scholar
• Sinues PM-L, Meier L, Berchtold C, et al. Breath analysis in real time by mass spectrometry in chronic obstructive pulmonary disease. Respiration. 2014;87:301–310.
   PubMed Web of Science ®Google Scholar
• Allers M, Langejuergen J, Gaida A, et al. Measurement of exhaled volatile organic compounds from patients with chronic obstructive pulmonary disease (COPD) using closed gas loop GC-IMS and GC-APCI-MS. J Breath Res. 2016;10:026004.
   PubMed Web of Science ®Google Scholar
• Gaida A, Holz O, Nell C, et al. A dual center study to compare breath volatile organic compounds from smokers and non-smokers with and without COPD. J Breath Res. 2016;10:026006.
   PubMed Web of Science ®Google Scholar
• Cristescu SM, Gietema HA, Blanchet L, et al. Screening for emphysema via exhaled volatile organic compounds. J Breath Res. 2011;5:046009.
   PubMed Web of Science ®Google Scholar
• (*NEW). 2017. GINA report: global strategy for asthma management and prevention. [Internet]. Glob. Initiat. Asthma - GINA. [cited 2018 Feb 13]. Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/
   Google Scholar
• Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med. 2013;19:977–979.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet Lond Engl. 2018;391:350–400.
   PubMed Web of Science ®Google Scholar
• Simpson JL, Scott R, Boyle MJ, et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirol Carlton Vic. 2006;11:54–61.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973–984.
   PubMed Web of Science ®Google Scholar
• Lazar Z, Fens N, van der Maten J, et al. Electronic nose breathprints are independent of acute changes in airway caliber in asthma. Sensors. 2010;10:9127–9138.
   PubMed Web of Science ®Google Scholar
• Dragonieri S, Schot R, Mertens BJA, et al. An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol. 2007;120:856–862.
   PubMed Web of Science ®Google Scholar
• Plaza V, Crespo A, Giner J, et al. Inflammatory asthma phenotype discrimination using an electronic nose breath analyzer. J Investig Allergol Clin Immunol. 2015;25:431–437.
   PubMed Web of Science ®Google Scholar
• Fens N, van der Sluijs KF, van de Pol MA, et al. Electronic nose identifies bronchoalveolar lavage fluid eosinophils in asthma. Am J Respir Crit Care Med. 2015;191:1086–1088.
   PubMed Web of Science ®Google Scholar
• van der Schee MP, Palmay R, Cowan JO, et al. Predicting steroid responsiveness in patients with asthma using exhaled breath profiling. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2013;43:1217–1225.
   PubMed Web of Science ®Google Scholar
• Ibrahim B, Basanta M, Cadden P, et al. Non-invasive phenotyping using exhaled volatile organic compounds in asthma. Thorax. 2011;66:804–809.
   PubMed Web of Science ®Google Scholar
• Meyer N, Dallinga JW, Nuss SJ, et al. Defining adult asthma endotypes by clinical features and patterns of volatile organic compounds in exhaled air. Respir Res. 2014;15:136.
   PubMed Web of Science ®Google Scholar
• Smolinska A, Klaassen EMM, Dallinga JW, et al. Profiling of volatile organic compounds in exhaled breath as a strategy to find early predictive signatures of asthma in children. PloS One. 2014;9:e95668.
   PubMed Web of Science ®Google Scholar
• Klaassen EMM, van de Kant KDG, Jöbsis Q, et al. Exhaled biomarkers and gene expression at preschool age improve asthma prediction at 6 years of age. Am J Respir Crit Care Med. 2015;191:201–207.
   PubMed Web of Science ®Google Scholar
• Brinkman P, van de Pol MA, Gerritsen MG, et al. Exhaled breath profiles in the monitoring of loss of control and clinical recovery in asthma. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2017;47:1159–1169.
   PubMed Web of Science ®Google Scholar
• Robroeks CM, van Berkel JJ, Jöbsis Q, et al. Exhaled volatile organic compounds predict exacerbations of childhood asthma in a 1-year prospective study. Eur Respir J. 2013;42:98–106.
   PubMed Web of Science ®Google Scholar
• van Vliet D, Smolinska A, Jöbsis Q, et al. Can exhaled volatile organic compounds predict asthma exacerbations in children?. J Breath Res. 2017;11:016016.
   PubMed Web of Science ®Google Scholar
• Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. Lancet Oncol. 2017;18:e754–e766.
   PubMed Web of Science ®Google Scholar
• National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
   PubMed Web of Science ®Google Scholar
• Ruano-Ravina A, Pérez-Ríos M, Casàn-Clará P, et al. Low-dose CT for lung cancer screening. Lancet Oncol. 2018;19:e131–e132.
   PubMedGoogle Scholar
• Sawicki LM, Grueneisen J, Buchbender C, et al. Evaluation of the outcome of lung nodules missed on 18F-FDG PET/MRI compared with 18F-FDG PET/CT in patients with known malignancies. J Nucl Med Off Publ Soc Nucl Med. 2016;57:15–20.
   PubMed Web of Science ®Google Scholar
• Machado RF, Laskowski D, Deffenderfer O, et al. Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med. 2005;171:1286–1291.
   PubMed Web of Science ®Google Scholar
• Gasparri R, Santonico M, Valentini C, et al. Volatile signature for the early diagnosis of lung cancer. J Breath Res. 2016;10:016007.
   PubMed Web of Science ®Google Scholar
• Dragonieri S, Annema JT, Schot R, et al. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer (Amst Neth). 2009;64:166–170.
   PubMed Web of Science ®Google Scholar
• Rocco R, Incalzi RA, Pennazza G, et al. BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes†. Eur J Cardio Thorac Surg Off J Eur Assoc Cardio Thorac Surg. 2016;49:1112–1117. discussion 1117.
   PubMed Web of Science ®Google Scholar
• Peled N, Hakim M, Bunn PA, et al. Non-invasive breath analysis of pulmonary nodules. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2012;7:1528–1533.
   Google Scholar
• Barash O, Peled N, Tisch U, et al. Classification of lung cancer histology by gold nanoparticle sensors. Nanomed Nanotechnol Biol Med. 2012;8:580–589.
   PubMed Web of Science ®Google Scholar
• Santonico M, Lucantoni G, Pennazza G, et al. In situ detection of lung cancer volatile fingerprints using bronchoscopic air-sampling. Lung Cancer (Amst Neth). 2012;77:46–50.
   PubMed Web of Science ®Google Scholar
• Peled N, Barash O, Tisch U, et al. Volatile fingerprints of cancer specific genetic mutations. Nanomed Nanotechnol Biol Med. 2013;9:758–766.
   PubMed Web of Science ®Google Scholar
• Shlomi D, Abud M, Liran O, et al. Detection of lung cancer and EGFR mutation by electronic nose system. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2017;12:1544–1551.
   Google Scholar
• Filipiak W, Filipiak A, Sponring A, et al. Comparative analyses of volatile organic compounds (VOCs) from patients, tumors and transformed cell lines for the validation of lung cancer-derived breath markers. J Breath Res. 2014;8:027111.
   PubMed Web of Science ®Google Scholar
• Phillips M, Altorki N, Austin JHM, et al. Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark Sect Dis Markers. 2007;3:95–109.
   PubMedGoogle Scholar
• Sakumura Y, Koyama Y, Tokutake H, et al. Diagnosis by volatile organic compounds in exhaled breath from lung cancer patients using support vector machine algorithm. Sensors. 2017;17: 287.
   Web of Science ®Google Scholar
• Kischkel S, Miekisch W, Sawacki A, et al. Breath biomarkers for lung cancer detection and assessment of smoking related effects–confounding variables, influence of normalization and statistical algorithms. Clin Chim Acta Int J Clin Chem. 2010;411:1637–1644.
   PubMed Web of Science ®Google Scholar
• Chen X, Wang F, Lin L, et al. Association of smoking with metabolic volatile organic compounds in exhaled breath. Int J Mol Sci. 2017;18:2235.
   Web of Science ®Google Scholar
• Schallschmidt K, Becker R, Jung C, et al. Comparison of volatile organic compounds from lung cancer patients and healthy controls-challenges and limitations of an observational study. J Breath Res. 2016;10:046007.
   PubMed Web of Science ®Google Scholar
• Capuano R, Santonico M, Pennazza G, et al. The lung cancer breath signature: a comparative analysis of exhaled breath and air sampled from inside the lungs. Sci Rep. 2015;5:16491.
   PubMed Web of Science ®Google Scholar
• Handa H, Usuba A, Maddula S, et al. Exhaled breath analysis for lung cancer detection using ion mobility spectrometry. PloS One. 2014;9:e114555.
   PubMed Web of Science ®Google Scholar
• Broza YY, Kremer R, Tisch U, et al. A nanomaterial-based breath test for short-term follow-up after lung tumor resection. Nanomed Nanotechnol Biol Med. 2013;9:15–21.
   PubMed Web of Science ®Google Scholar
• Poli D, Carbognani P, Corradi M, et al. Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res. 2005;6:71.
   PubMed Web of Science ®Google Scholar
• Kischkel S, Miekisch W, Fuchs P, et al. Breath analysis during one-lung ventilation in cancer patients. Eur Respir J. 2012;40:706–713.
   PubMedGoogle Scholar
• Nardi-Agmon I, Abud-Hawa M, Liran O, et al. Exhaled breath analysis for monitoring response to treatment in advanced lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2016;11:827–837.
   Google Scholar
• Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001;163:19–25.
   PubMed Web of Science ®Google Scholar
• Yaggi HK, Concato J, Kernan WN, et al. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005;353:2034–2041.
   PubMed Web of Science ®Google Scholar
• Dixon JB, Schachter LM, O’Brien PE. Predicting sleep apnea and excessive day sleepiness in the severely obese: indicators for polysomnography. Chest. 2003;123:1134–1141.
   PubMed Web of Science ®Google Scholar
• Scarlata S, Pedone C, Curcio G, et al. Pre-polysomnographic assessment using the Pittsburgh Sleep Quality Index questionnaire is not useful in identifying people at higher risk for obstructive sleep apnea. J Med Screen. 2013;20:220–226.
   PubMed Web of Science ®Google Scholar
• Scarlata S, Pennazza G, Santonico M, et al. Screening of obstructive sleep apnea syndrome by electronic-nose analysis of volatile organic compounds. Sci Rep. 2017;7:11938.
   PubMed Web of Science ®Google Scholar
• Greulich T, Hattesohl A, Grabisch A, et al. Detection of obstructive sleep apnoea by an electronic nose. Eur Respir J. 2013;42:145–155.
   PubMed Web of Science ®Google Scholar
• Dragonieri S, Quaranta VN, Carratu P, et al. Exhaled breath profiling in patients with COPD and OSA overlap syndrome: a pilot study. J Breath Res. 2016;10:041001.
   PubMed Web of Science ®Google Scholar
• Benedek P, Lázár Z, Bikov A, et al. Exhaled biomarker pattern is altered in children with obstructive sleep apnoea syndrome. Int J Pediatr Otorhinolaryngol. 2013;77:1244–1247.
   PubMed Web of Science ®Google Scholar
• Kunos L, Bikov A, Lazar Z, et al. Evening and morning exhaled volatile compound patterns are different in obstructive sleep apnoea assessed with electronic nose. Sleep Breath Schlaf Atm. 2015;19:247–253.
   PubMed Web of Science ®Google Scholar
• Burioka N, Miyata M, Fukuoka Y, et al. Day-night variations of serum interleukin-6 in patients with severe obstructive sleep apnea syndrome before and after continuous positive airway pressure (CPAP). Chronobiol Int. 2008;25:827–834.
   PubMed Web of Science ®Google Scholar
• Antonelli Incalzi R, Pennazza G, Scarlata S, et al. Comorbidity modulates non invasive ventilation-induced changes in breath print of obstructive sleep apnea syndrome patients. Sleep Breath Schlaf Atm. 2015;19:623–630.
   PubMed Web of Science ®Google Scholar
• Humphreys L, Orme RML, Moore P, et al. Electronic nose analysis of bronchoalveolar lavage fluid. Eur J Clin Invest. 2011;41:52–58.
   PubMed Web of Science ®Google Scholar
• van Oort PMP, de Bruin S, Weda H, et al. Exhaled breath metabolomics for the diagnosis of pneumonia in intubated and mechanically-ventilated intensive care unit (ICU)-patients. Int J Mol Sci. 2017;18:449.
   Web of Science ®Google Scholar
• Schnabel RM, Boumans MLL, Smolinska A, et al. Electronic nose analysis of exhaled breath to diagnose ventilator-associated pneumonia. Respir Med. 2015;109:1454–1459.
   PubMed Web of Science ®Google Scholar
• Gao J, Zou Y, Wang Y, et al. Breath analysis for noninvasively differentiating Acinetobacter baumannii ventilator-associated pneumonia from its respiratory tract colonization of ventilated patients. J Breath Res. 2016;10:027102.
   PubMed Web of Science ®Google Scholar
• Bos LDJ, Martin-Loeches I, Kastelijn JB, et al. The volatile metabolic fingerprint of ventilator-associated pneumonia. Intensive Care Med. 2014;40:761–762.
   PubMed Web of Science ®Google Scholar
• de Heer K, Kok MGM, Fens N, et al. Detection of airway colonization by Aspergillus fumigatus by use of electronic nose technology in patients with cystic fibrosis. J Clin Microbiol. 2016;54:569–575.
   PubMed Web of Science ®Google Scholar
• de Heer K, van der Schee MP, Zwinderman K, et al. Electronic nose technology for detection of invasive pulmonary aspergillosis in prolonged chemotherapy-induced neutropenia: a proof-of-principle study. J Clin Microbiol. 2013;51:1490–1495.
   PubMed Web of Science ®Google Scholar
• Zetola NM, Modongo C, Matsiri O, et al. Diagnosis of pulmonary tuberculosis and assessment of treatment response through analyses of volatile compound patterns in exhaled breath samples. J Infect. 2017;74:367–376.
   PubMed Web of Science ®Google Scholar
• Teixeira CR, Rodríguez M, de Romero JN, et al. The potential of a portable, point-of-care electronic nose to diagnose tuberculosis. J Infect. 2017;75:441–447.
   PubMed Web of Science ®Google Scholar
• Bruins M, Rahim Z, Bos A, et al. Diagnosis of active tuberculosis by e-nose analysis of exhaled air. Tuberc Edinb Scotl. 2013;93:232–238.
   PubMed Web of Science ®Google Scholar
• Phillips M, Basa-Dalay V, Bothamley G, et al. Breath biomarkers of active pulmonary tuberculosis. Tuberc Edinb Scotl. 2010;90:145–151.
   PubMed Web of Science ®Google Scholar
• MacKenzie T, Gifford AH, Sabadosa KA, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the cystic fibrosis foundation patient registry. Ann Intern Med. 2014;161:233–241.
   PubMed Web of Science ®Google Scholar
• Paff T, van der Schee MP, Daniels JMA, et al. Exhaled molecular profiles in the assessment of cystic fibrosis and primary ciliary dyskinesia. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2013;12:454–460.
   PubMed Web of Science ®Google Scholar
• Robroeks CMHHT, van Berkel JJBN, Dallinga JW, et al. Metabolomics of volatile organic compounds in cystic fibrosis patients and controls. Pediatr Res. 2010;68:75–80.
   PubMed Web of Science ®Google Scholar
• Španěl P, Sovová K, Dryahina K, et al. Do linear logistic model analyses of volatile biomarkers in exhaled breath of cystic fibrosis patients reliably indicate Pseudomonas aeruginosa infection? J. Breath Res. 2016;10:036013.
   PubMed Web of Science ®Google Scholar
• Neerincx AH, Geurts BP, van Loon J, et al. Detection of staphylococcus aureus in cystic fibrosis patients using breath VOC profiles. J Breath Res. 2016;10:046014.
   PubMed Web of Science ®Google Scholar
• Joensen O, Paff T, Haarman EG, et al. Exhaled breath analysis using electronic nose in cystic fibrosis and primary ciliary dyskinesia patients with chronic pulmonary infections. PloS One. 2014;9:e115584.
   PubMed Web of Science ®Google Scholar
• Paredi P, Kharitonov SA, Leak D, et al. Exhaled ethane is elevated in cystic fibrosis and correlates with carbon monoxide levels and airway obstruction. Am J Respir Crit Care Med. 2000;161:1247–1251.
   PubMed Web of Science ®Google Scholar
• Barker M, Hengst M, Schmid J, et al. Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis. Eur Respir J. 2006;27:929–936.
   PubMed Web of Science ®Google Scholar
• Kamboures MA, Blake DR, Cooper DM, et al. Breath sulfides and pulmonary function in cystic fibrosis. Proc Natl Acad Sci U S A. 2005;102:15762–15767.
   PubMed Web of Science ®Google Scholar
• McGrath LT, Patrick R, Mallon P, et al. Breath isoprene during acute respiratory exacerbation in cystic fibrosis. Eur Respir J. 2000;16:1065–1069.
   PubMed Web of Science ®Google Scholar
• Dragonieri S, Brinkman P, Mouw E, et al. An electronic nose discriminates exhaled breath of patients with untreated pulmonary sarcoidosis from controls. Respir Med. 2013;107:1073–1078.
   PubMed Web of Science ®Google Scholar
• Chapman EA, Thomas PS, Stone E, et al. A breath test for malignant mesothelioma using an electronic nose. Eur Respir J. 2012;40:448–454.
   PubMed Web of Science ®Google Scholar
• Dragonieri S, van der Schee MP, Massaro T, et al. An electronic nose distinguishes exhaled breath of patients with malignant pleural mesothelioma from controls. Lung Cancer (Amst Neth). 2012;75:326–331.
   PubMed Web of Science ®Google Scholar
• Fens N, Douma RA, Sterk PJ, et al. Breathomics as a diagnostic tool for pulmonary embolism. J Thromb Haemost. 2010;8:2831–2833.
   PubMed Web of Science ®Google Scholar
• Yamada Y-I, Yamada G, Otsuka M, et al. Volatile organic compounds in exhaled breath of idiopathic pulmonary fibrosis for discrimination from healthy subjects. Lung. 2017;195:247–254.
   PubMed Web of Science ®Google Scholar
• Timms C, Thomas PS, Yates DH. Detection of gastro-oesophageal reflux disease (GORD) in patients with obstructive lung disease using exhaled breath profiling. J Breath Res. 2012;6:016003.
   PubMed Web of Science ®Google Scholar
• Beck JM, Young VB, Huffnagle GB. The microbiome of the lung. Transl Res J Lab Clin Med. 2012;160:258–266.
   Google Scholar
• Man WH, de Steenhuijsen Piters WAA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol. 2017;15:259–270.
   PubMed Web of Science ®Google Scholar
• Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the “healthy” smoker and in COPD. PloS One. 2011;6:e16384.
   PubMed Web of Science ®Google Scholar
• Lu J, Xiong L, Zhang X, et al. The role of lower airway dysbiosis in asthma: dysbiosis and asthma. Mediators Inflamm. [Internet]. 2017. [cited 2018 Feb 11]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745728/
   Web of Science ®Google Scholar
• Sv L. The lung microbiome and airway disease. Ann Am Thorac Soc. 2016;13:S462–S465.
   PubMed Web of Science ®Google Scholar
• Mittal S, Brown NJ, Holen I. The breast tumor microenvironment: role in cancer development, progression and response to therapy. Expert Rev Mol Diagn. 2018;18:227–243.
   PubMed Web of Science ®Google Scholar
• Vetrano DL, Calderón-Larrañaga A, Marengoni A, et al. An International Perspective on Chronic Multimorbidity: Approaching the Elephant in the Room. J. Gerontol. Ser. A. 2018;73:1350–1356.
   Google Scholar